Mabwell (Shanghai) Bioscience Co., Ltd.
🇨🇳China
- Country
- 🇨🇳China
- Ownership
- Public, Subsidiary
- Established
- 2017-05-12
- Employees
- 1.4K
- Market Cap
- -
- Website
- https://www.mabwell.com
Clinical Trials
45
Active:3
Completed:10
Trial Phases
4 Phases
Phase 1:28
Phase 2:9
Phase 3:7
+1 more phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (45 trials with phase data)• Click on a phase to view related trials
Phase 1
28 (62.2%)Phase 2
9 (20.0%)Phase 3
7 (15.6%)Not Applicable
1 (2.2%)First-in-human Study of 7MW4911 in GI Cancer
Not Applicable
Not yet recruiting
- Conditions
- GI Cancers
- Interventions
- Drug: 7MW4911
- First Posted Date
- 2025-10-14
- Last Posted Date
- 2025-10-14
- Lead Sponsor
- Mabwell (Shanghai) Bioscience Co., Ltd.
- Target Recruit Count
- 200
- Registration Number
- NCT07216560
A Clinical Study of 9MW2821 Monotherapy or Combined With Other Anticancer Therapy in Advanced Solid Tumors
Phase 1
Not yet recruiting
- Conditions
- Solid Tumors
- Interventions
- Drug: Other anti-cancer therapy
- First Posted Date
- 2025-04-27
- Last Posted Date
- 2025-04-27
- Lead Sponsor
- Mabwell (Shanghai) Bioscience Co., Ltd.
- Target Recruit Count
- 188
- Registration Number
- NCT06947226
- Locations
- 🇨🇳
The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China
9MW2821 Combined With Other Antitumor Drugs in Patients With Advanced Gynecological Tumors
Phase 1
Not yet recruiting
- Conditions
- Gynecological Malignancies
- Interventions
- Drug: 9MW2821+other anticancer therapy
- First Posted Date
- 2025-04-15
- Last Posted Date
- 2025-04-15
- Lead Sponsor
- Mabwell (Shanghai) Bioscience Co., Ltd.
- Target Recruit Count
- 260
- Registration Number
- NCT06926998
- Locations
- 🇨🇳
Zhejiang Cancer Hospital, Hangzhou, Zhejiang, China
A Dose Randomization Study of Bulumtatug Fuvedotin in TNBC Patients Previously Treated With ADCs
Phase 1
Recruiting
- Conditions
- Triple Negative Breast Cancer
- Interventions
- Drug: bulumtatug fuvedotin
- First Posted Date
- 2025-04-03
- Last Posted Date
- 2025-09-23
- Lead Sponsor
- Mabwell (Shanghai) Bioscience Co., Ltd.
- Target Recruit Count
- 52
- Registration Number
- NCT06908928
- Locations
- 🇺🇸
City of Hope, Duarte, California, United States
🇺🇸UCSD Moores Cancer Center, La Jolla, California, United States
🇺🇸UChicago Medicine Comprehensive Cancer Center, Chicago, Illinois, United States
9MW2821 + Toripalimab vs 9MW2821 for 1st Line Locally Advanced or Metastatic Urothelial Carcinoma
Phase 2
Recruiting
- Conditions
- Urothelial CarcinomaUrothelial Carcinoma BladderUrothelial Carcinoma RecurrentUrothelial Carcinoma of the Renal Pelvis and Ureter
- Interventions
- First Posted Date
- 2025-02-12
- Last Posted Date
- 2025-03-21
- Lead Sponsor
- Mabwell (Shanghai) Bioscience Co., Ltd.
- Target Recruit Count
- 60
- Registration Number
- NCT06823427
- Locations
- 🇨🇳
Hunan Tumor Hospital, Changsha, Hunan, China
🇨🇳Nanjing Drum Tower Hospital, Nanjing, Jiangsu, China
- Prev
- 1
- 2
- 3
- 4
- 5
- 9
- Next
News
No news found